AT
Attovia TherapeuticsAttovia Therapeutics is a clinical-stage biotech developing ATTOBODY-based biotherapeutics for immune-mediated diseases that went public on Nasdaq in August 2026 in an upsized IPO raising ~$332M gross.
8 Pulse stories
P
PureTechPureTech Health is a publicly traded biopharmaceutical company that discovers, develops, and commercializes breakthrough medicines by founding and funding a network of subsidiary companies, including Celea Therapeutics.
2 Pulse stories
Total Raised
~$588M ($256M private + $332M IPO gross incl. greenshoe, Aug 2026)
Attovia TherapeuticsPureTech
Last Valuation
$767M at IPO pricing; ~$904M market cap at Nasdaq open (Aug 5, 2026)
Attovia TherapeuticsPureTech
Biotech
Sector
Biotech
2023
Founded
2005
San Carlos, CA
HQ
Boston, Massachusetts
Public (ATTO)
Status
Public (PRTC)
Attovia Therapeutics investors
venBio PartnersGoldman Sachs AlternativesFrazier Life SciencesDeep Track CapitalIllumina VenturesSanofi VenturesEcoR1 Capital
PureTech investors
No investors on record.
Data from Value Add Pulse coverage and company research — see the full threads for Attovia Therapeutics and PureTech.